Answers are grounded in this paper and cite their sources.
The cellular basis of COVID-19 severity in patients with deficiencies in type I IFN immunity remains unclear. In this study, we differentiated cardiomyocytes and macrophages from IFNAR1 competent (IFNAR1 comp ) and deficient (IFNAR1 def ) induced pluripotent stem cells (iPSCs), and analyzed virus replication and cytokine production after exposure to SARS-CoV-2. Cardiomyocytes expressed the SARS-CoV-2 receptor angiotensin-converting enzyme 2 (ACE2) and showed abundant SARS-CoV-2 replication, which was higher in IFNAR1 def than IFNAR1 comp cells. Treatment with exogenous IFNα mitigated infection in IFNAR1 comp , but not in IFNAR1 def cardiomyocytes. In contrast, macrophages did not express ACE2 and did not support SARS-CoV-2 replication, but produced pro-inflammatory cytokines upon virus exposure, which was impaired in IFNAR1 def macrophages. In conclusion, type I IFNs decrease SARS-CoV-2 replication in human iPSC-derived cardiomyocytes, while they increase cytokine responses of macrophages.
No takes yet. Share an insight, caveat, or question.
Durán et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: